Durvalumab is primarily used in the treatment of certain types of cancer. It is a monoclonal antibody that works by helping the immune system attack cancer cells. Specifically, it is approved for the treatment of non-small cell lung cancer (NSCLC) in patients whose cancer has not spread widely and cannot be removed by surgery. It is used after these patients have undergone chemotherapy and radiation. Durvalumab is also used in the treatment of advanced bladder cancer, particularly for patients whose cancer has progressed during or after platinum-containing chemotherapy. By targeting the PD-L1 protein, it helps to block the mechanisms that cancer cells use to evade the immune system, thereby enhancing the body's ability to fight the disease.

The use of Durvalumab must be under the supervision of a specialist physician, as it may have serious side effects, such as allergic reactions, respiratory system problems, or effects on other internal organs. Patients should be closely monitored during treatment.